The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat

Neuropharmacology
Anna VasilakiKyriaki Thermos

Abstract

The aim of the present study was to examine the function of the somatostatin receptor (sst(1)) in the nucleus accumbens (NAc) of the basal ganglia. Radioligand binding studies were performed in rats to assess the presence of the receptor, while in vivo microdialysis studies were performed to examine its role in somatostatin release. CH-275, which is selective for sst(1), MK-678, selective for sst(2) and L-803,087, selective for sst(4) receptors displaced [(125)I]-Tyr(11)-somatostatin specific binding in a concentration-dependent manner with IC(50) values of 75, 0.21 and 11 nM, respectively. Infusion of CH-275 (10(-5), 10(-6) or 10(-7) M) in the NAc of freely moving rats resulted in a decrease in somatostatin levels only at the concentration of 10(-5) M. This effect was reversed by 10(-5) M of the selective sst(1) antagonist SRA-880. The sst(1) agonist L-797,591 (10(-5) M) mimicked the effect of CH-275, while MK-678 and L-803,087 at the same concentration were unable to influence somatostatin levels. These results provide functional evidence to demonstrate that the sst(1) receptor modulates somatostatin release in the basal ganglia.

References

Jun 1, 1975·Endocrinology·M BrownsteinJ S Kizer
Mar 1, 1995·Trends in Pharmacological Sciences·D HoyerJ E Taylor
Apr 13, 1999·Neuroscience·M HändelV Höllt
Dec 1, 1999·British Journal of Pharmacology·G J HathwayK M Kendrick
Nov 23, 2000·Journal of Physiology, Paris·S L Cole, M Schindler
May 11, 2001·Neuropeptides·Z Csaba, P Dournaud
Feb 4, 2003·Journal of Neurochemistry·Anna VasilakiKyriaki Thermos
May 22, 2003·Naunyn-Schmiedeberg's Archives of Pharmacology·Catherine VideauJacques Epelbaum
Jan 30, 2004·Neuroscience Letters·Niki Mastrodimou, Kyriaki Thermos

❮ Previous
Next ❯

Citations

Apr 9, 2009·Journal of Medicinal Chemistry·Judit ErchegyiJean Claude Reubi
Sep 19, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eleftherios PallisKyriaki Thermos
Jun 27, 2006·The AAPS Journal·Yanjun LiHartmut Derendorf
Mar 12, 2013·International Journal of Peptides·Federica BarbieriTullio Florio
May 18, 2007·Bioorganic & Medicinal Chemistry Letters·Thomas TroxlerKonstanze Hurth
Sep 27, 2005·Neuroscience Letters·Evangelia KouvidiKyriaki Thermos
Nov 9, 2005·Pharmacology & Therapeutics·Kyriaki ThermosDaniel Hoyer
Nov 19, 2005·Neuroscience Letters·Eleftherios G PallisKyriaki Thermos
Jul 1, 2014·The Journal of Comparative Neurology·Gregory S ParksOlivier Civelli
May 25, 2012·Journal of Neurophysiology·Violeta G López-HuertaElvira Galarraga
May 2, 2018·Psychopharmacology·Agata Faron-GóreckaMarta Dziedzicka-Wasylewska
Feb 14, 2008·Neurochemical Research·Violeta Gisselle Lopez-HuertaElvira Galarraga
Jan 22, 2005·Journal of Medicinal Chemistry·Judit ErchegyiJean E Rivier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.